Literature DB >> 35438379

Peripheral blood and urine metabolites and biological functions in post-stroke depression.

Haiyan Liu1, Juncai Pu2, Qinxiang Zhou1, Lining Yang3, Dingqun Bai4.   

Abstract

Post-stroke depression (PSD) is the most common and severe neuropsychiatric complication after stroke. However, the molecular mechanism of PSD is still unclear. Previous studies have identified peripheral blood and urine metabolites associated with PSD using metabolomics techniques. We searched and systematically summarized metabolites that may be involved in metabolic changes in peripheral blood and urine of patients with PSD from the Metabolite Network of Depression Database (MENDA) and other biomedical databases. MetaboAnalyst5.0 software was used for pathway analysis and enrichment analysis of differential metabolites, and subgroup analyses were performed according to tissue types and metabolomics techniques. We identified 47 metabolites that were differentially expressed between patients with and without PSD. Five differential metabolites were found in both plasma and urine, including L-glutamic acid, pyroglutamic acid, palmitic acid, L-phenylalanine, and L-tyrosine. We integrated these metabolites into metabolic pathways, and six pathways were significantly altered. These pathways could be roughly divided into three modules including amino acid metabolism, nucleotide metabolism, and glucose metabolism. Among them, the most significantly altered pathway was "phenylalanine metabolism" and the pathway containing the most associated metabolites was "aminoacyl-tRNA biosynthesis", which deserve further study to elucidate their role in the molecular mechanism of PSD. In summary, metabolic changes in peripheral blood and urine are associated with PSD, especially the disruption of "phenylalanine metabolism" and "aminoacyl-tRNA biosynthesis" pathways. This study provides clues to the metabolic characteristics of patients with PSD, which may help to elucidate the molecular pathogenesis of PSD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biofluids; Enrichment analysis; Metabolomics; Pathway analysis; Post-stroke depression

Mesh:

Substances:

Year:  2022        PMID: 35438379     DOI: 10.1007/s11011-022-00984-9

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.655


  54 in total

Review 1.  Metabolomics for laboratory diagnostics.

Authors:  Renata Bujak; Wiktoria Struck-Lewicka; Michał J Markuszewski; Roman Kaliszan
Journal:  J Pharm Biomed Anal       Date:  2014-12-25       Impact factor: 3.935

2.  The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach.

Authors:  Dmitry Frank; Ruslan Kuts; Philip Tsenter; Benjamin F Gruenbaum; Yulia Grinshpun; Vladislav Zvenigorodsky; Ilan Shelef; Dmitry Natanel; Evgeny Brotfain; Alexander Zlotnik; Matthew Boyko
Journal:  Neuropharmacology       Date:  2019-05-31       Impact factor: 5.250

3.  Post stroke depression and risk of stroke recurrence and mortality: A systematic review and meta-analysis.

Authors:  Wa Cai; Christoph Mueller; Yi-Jing Li; Wei-Dong Shen; Robert Stewart
Journal:  Ageing Res Rev       Date:  2019-01-31       Impact factor: 10.895

4.  Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls.

Authors:  Mariska Bot; Yuri Milaneschi; Tahani Al-Shehri; Najaf Amin; Sanzhima Garmaeva; Gerrit L J Onderwater; Rene Pool; Carisha S Thesing; Lisanne S Vijfhuizen; Nicole Vogelzangs; Ilja C W Arts; Ayse Demirkan; Cornelia van Duijn; Marleen van Greevenbroek; Carla J H van der Kallen; Sebastian Köhler; Lannie Ligthart; Arn M J M van den Maagdenberg; Dennis O Mook-Kanamori; Renée de Mutsert; Henning Tiemeier; Miranda T Schram; Coen D A Stehouwer; Gisela M Terwindt; Ko Willems van Dijk; Jingyuan Fu; Alexandra Zhernakova; Marian Beekman; P Eline Slagboom; Dorret I Boomsma; Brenda W J H Penninx
Journal:  Biol Psychiatry       Date:  2019-08-29       Impact factor: 13.382

5.  Divergent Urinary Metabolic Phenotypes between Major Depressive Disorder and Bipolar Disorder Identified by a Combined GC-MS and NMR Spectroscopic Metabonomic Approach.

Authors:  Jian-Jun Chen; Chan-Juan Zhou; Zhao Liu; Yu-Ying Fu; Peng Zheng; De-Yu Yang; Qi Li; Jun Mu; You-Dong Wei; Jing-Jing Zhou; Hua Huang; Peng Xie
Journal:  J Proteome Res       Date:  2015-07-20       Impact factor: 4.466

6.  A multivariate analysis of red blood cell membrane transports and plasma levels of L-tyrosine and L-tryptophan in depressed patients before treatment and after clinical improvement.

Authors:  P Chiaroni; J M Azorin; P Bovier; J Widmer; R Jeanningros; A Barré; H Dufour; A Tatossian; R Tissot
Journal:  Neuropsychobiology       Date:  1990       Impact factor: 2.328

7.  Plasma levels of glutamate during stroke is associated with development of post-stroke depression.

Authors:  Sai-Yu Cheng; Yan-Dong Zhao; Jie Li; Xiao-Yan Chen; Ruo-Dan Wang; Jun-Wei Zeng
Journal:  Psychoneuroendocrinology       Date:  2014-05-17       Impact factor: 4.905

8.  A metabonomic investigation on the biochemical perturbation in post-stroke patients with depressive disorder (PSD).

Authors:  Xinghua Ding; Ruoxu Liu; Wenkai Li; Hengjia Ni; Yong Liu; Dandan Wu; Shuguang Yang; Jing Liu; Bo Xiao; Shaojun Liu
Journal:  Metab Brain Dis       Date:  2015-11-05       Impact factor: 3.584

Review 9.  Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments.

Authors:  Killian Ashe; Wendy Kelso; Sarah Farrand; Julie Panetta; Tim Fazio; Gerard De Jong; Mark Walterfang
Journal:  Front Psychiatry       Date:  2019-09-10       Impact factor: 4.157

10.  Urinary Metabolite Signatures for Predicting Elderly Stroke Survivors with Depression.

Authors:  Jin Chen; Yan-Ni Lv; Xiao-Bing Li; Jia-Jun Xiong; Hui-Ting Liang; Liang Xie; Chen-Yi Wan; Yun-Qing Chen; Han-Sen Wang; Pan Liu; He-Qing Zheng
Journal:  Neuropsychiatr Dis Treat       Date:  2021-03-25       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.